Introduction
Brainstem gliomas (BSG) are rare tumors in the adult population, accounting for 1.5-2.5% of all intracranial tumors in adults 1, 2 . Malignant BSG account for approximately 31-39% of the cases of adults with BSG 3, 4 . Although not routinely used to make the diagnosis, histologic examination reveals a World Heath Organization (WHO) grade III or IV glioma in most cases. Radiographically, these lesions exhibit contrast enhancement, often in a ring-like appearance 3 . The median survival of patients with maligant BSG tumors has been documented to be 44-74 weeks, with fractionated radiotherapy representing the only effective treatment 5 .
Studies incorporating bevacizumab in the treatment of recurrent supratentorial malignant tumors have demonstrated up to 50% six month progression-free survival (PSF) 6 . Although the role for this agent up front or at relapse in the treatment of BSG has not been fully established, a recent case report utilizing bevacizumab and irinotecan in an adult with progressive brainstem glioma demonstrated encouraging results, with clinical and radiographic results similar to those of supratentorial disease.
Recently, we published the technical feasibil-
Summary
Malignant brainstem gliomas (BSG) are rare tumors in adults, associated with a grim prognosis and limited treatment options. Currently, radiotherapy represents the mainstay of treatment, although new studies suggest an increased role for certain chemotherapeutic agents. Intravenous (IV) administration of bevacizumab (Avastin, Genentech Pharmaceuticals) has been shown to be active in the treatment of some enhancing malignant brainstem gliomas. The IV route of administration, however, carries a risk of systemic side effects such as bowel perforation, wound disrepair and pulmonary embolism. In addition, the percentage of IV drug that reaches the tumor site is restricted by the blood brain barrier (BBB).
This technical report describes our protocol in performing superselective intra-arterial cerebral infusion (SIACI) of bevacizumab using endovascular balloon-assistance in the top of the basilar artery in a patient with a recurrent malignant brainstem glioma. It represents the first time such a technique has been performed for this disease.
This method of drug delivery may have important implications in the treatment of both adult and pediatric brainstem gliomas.
ity of SIACI of mannitol followed by bevacizumab for the treatment of recurrent malignant supratentorial disease 7 . The protocol for selective infusion includes focal disruption of the BBB and high-dose first-pass infusion of the chemotherapy directly to the target. Given the preliminary data using IV bevacizumab, we wanted to test the hypothesis that SIACI of bevacizumab after BBB disruption would be effective in the treatment of malignant brainstem tumors. This report details the protocol of using endovascular balloon-assistance at the top of the basilar artery to increase brainstem penetration of the chemotherapy bevacizumab. If proven both safe and effective in larger trials, this novel delivery method may offer a better way to treat BSGs both in adults and children.
Materials and Methods

Case History
A 43-year-old male with a diagnosis of malignant BSG was treated at an outside institution with several cycles of temodar and fractionated radiotherapy. Additionally, he received 12 doses of IV bevacizumab with good tolerability and side-effects. Tissue biopsy was never performed, and diagnosis was established by radiographic and clinical criteria. The patient presented to the Weill Cornell Brain Tu-mor Center in December, 2009 approximately nine months after the original diagnosis with progressive complaints of diplopia and leftsided hemiparesis resulting in wheelchair dependence.
On physical examination, the patient was noted to have right VI and lower motor neuron VII nerve palsies. All other cranial nerves were intact. He was mentating well with no complaints or evidence of cognitive decline or memory impairment. He displayed a dense leftsided spastic hemiparesis, worse in the lower extremities.
Radiographic studies including gadoliniumweighted magnetic resonance imaging (MRI) demonstrated an expansile and heterogeneously T2 hyperintense mass centered within the inferior pons which extended down to the upper medulla. In addition, a 7 mm area of focal enhancement was present on the ventral lateral aspect of the pons (Figure 1 ). The patient underwent balloon-assisted SIACI of mannitol and bevacizumab. The protocol was approved by the Institutional Review Board (IRB) at Weill Cornell Medical College.
Follow-up MRI performed 24 hours after balloon-assisted SIACI of mannitol and bevacizumab demonstrated a marked improvement in the appearance of gadolinium enhancement in the pontine region where the chemotherapy Figure 1 Contrast-enhanced T1-weighted MRI of the brain before superselective intra-arterial cerebral infusion of bevacizumab demonstrating brainstem glioma with nodular enhancement at the ventral lateral aspect of the pons.
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had been targeted compared to pre-infusion sequences ( Figure 4 ). There were no adverse events associated with the delivery of chemotherapy. The patient continues to remain clinically stable without any systemic or local sideeffects of the treatment protocol.
Technical aspects of the balloon-assisted superselective intra-arterial procedure
The procedure was performed with the patient intubated under general anesthesia. The common femoral artery was accessed with a 19gauge needle which was exchanged for a 6 French Sheath. A 6 French guide catheter was then advanced into the mid-cervical segment of the right vertebral artery. Biplane angiography over the cranium from a right vertebral artery injection demonstrated the basilar artery and its branches in the region of the pontine glioma. After administering intravenous weightbased heparin, a Hyperglide 7 x 7 balloon (ev3 Neurovascular, Irvine, CA, USA) was advanced over a microwire into the basilar artery distal to the site of planned intra-arterial infusion of mannitol/bevacizumab. Next, a micro-catheter was advanced over a microwire through the guide catheter into the lower aspect of the basilar artery at the right vertebrobasilar junction. The catheter was positioned to give maximal infusion along that segment of the basilar artery where the perforators supplying the pons arise. Next, 10 cc of 25% mannitol was infused through the microcatheter over two minutes with the balloon inflated in the distal basilar artery to occlude flow of the medication to non-targeted areas in the distal posterior circulation (Figure 2 ). Post- infusion angiography demonstrated increased hyperemia in the vasculature supplying the tumor-infiltrated pons as compared to pre-infusion sequences, suggesting that the BBB had been disrupted (Figure 3) . The hyperemia following disruption of the blood brain barrier has been observed in the other participants of the trial. Next, 8 mg/kg of bevacizumab in 36 cc was selectively infused through the microcatheter at 1 cc/min with the balloon inflated in the distal basilar artery to occlude flow of chemotherapy to non-targeted areas in the distal posterior circulation. The bevacizumab was infused over the course of three minutes with the balloon inflated, the balloon was then deflated for approximately two minutes to allow blood flow to the posterior circulation, and reinfusion with the balloon inflated was resumed. This was repeated for 36 minutes until all 36 cc of solution had been selectively infused. At the end of the procedure, all catheters were removed. There was no evidence of vascular injury.
Discussion
Bevacizumab is a monoclonal antibody that binds to vascular endothelial growth factor (VEGF) and blocks the formation of new blood vessels, but also affects existing vasculature. Anti-angiogenic therapy may normalize the structure and function of blood vessels and decrease tumor-related edema. Recent studies demonstrating the effectiveness of bevacizumab has established it as a standard, both alone or in combination with other agents, in the treatment of recurrent malignant supratentorial tumors. Despite the encouraging results from phase II trials utilizing IV bevacizumab for recurrent disease 6, 8 , systemic toxicity has been noted with its use, including infections, venous thromboembolic events, and wound-healing complications occurring in 9.5%, 2.4%, and 3.6%, respectively [9] [10] [11] [12] [13] . In addition, a 46.4% rate of Grade 3 or higher toxicity was seen in patients who received bevacizumab as monotherapy 14 . Although the FDA has approved its systemic use in recurrent malignant disease, we have used SIACI delivery of the drug both to improve clinical efficacy rates and decrease systemic side-effect profiles.
The use of intra-arterial delivery of chemotherapy has been shown to be advantageous to IV dosing in cerebral disease in both animal models of glioma and human studies 15 . In addi-tion, techniques for BBB disruption with osmotic agents have been developed and safely utilized with chemotherapy infusion for over 20 years [16] [17] [18] [19] . Hall et Al. described eight patients who received monthly intra-arterial infusion of mannitol followed by carboplatin or methotrexate in addition to IV antineoplastic treatment protocols and radiation therapy. Despite their small sample size, the results were encouraging, with median PFS times of 15 months and median survival times of 27 months 20 . Their study, however, did not utilize microcatheters for selective delivery of the osmotic agent and antineoplastic drug to the pontine region or distal balloon occlusion to prevent washout to the posterior circulation. This is the first case report describing balloon-assisted SIACI of an osmotic agent and bevacizumab for malignant BSG. The efficacy of the balloon was demonstrated by no distal contrast flow on the angiogram during inflation, and the efficacy of BBB disruption represented by increased vascular hyperemia in the region of interest. This brief hyperemia allows for increased exposure of the monoclonal antibody bevacizumab to tumor vascular endothelial growth factor targets. The immediate decrease in tumor enhancement following this treatment protocol confirms accurate delivery to the area of interest, and argues for follow-up studies utilizing larger cohorts of patients to define therapeutic efficacy. In addition, future trials with the application of radiolabeled tracers such as 64Cu-DOTA-bevacizumab will afford more precise localization of CNS distribution of chemotherapy after SIACI.
Conclusions
In view of recent studies suggesting the improved efficacy profile of IV bevacizumab on survival in patients with recurrent malignant supratentorial glioma, we have combined this treatment protocol with endovascular techniques for accurate and selective disruption of the BBB before chemotherapy infusion. This technical report describes the method of balloon-assisted SIACI of bevacizumab after BBB disruption for malignant brainstem gliomas. If proven safe and effective in a larger cohort of patients, this paradigm may significantly alter the way chemotherapies are delivered to patients with both diffusely infiltrating low grade, and high grade malignant brainstem gliomas.
